17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
Recruiting in Palo Alto (17 mi)
EH
Overseen byElisabeth Heath
Age: 18+
Sex: Male
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: National Cancer Institute (NCI)
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
This phase II trial is studying how well 17-AAG works in treating patients with metastatic prostate cancer that did not respond to previous hormone therapy. Drugs used in chemotherapy, such as 17-AAG, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Research Team
EH
Elisabeth Heath
Principal Investigator
Mayo Clinic
Eligibility Criteria
Inclusion Criteria
Histologically confirmed adenocarcinoma of the prostate
Metastatic disease
Measurable or evaluable disease
See 7 more
Treatment Details
Interventions
- 17-AAG (Heat Shock Protein Inhibitor)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Treatment (tanespimycin)Experimental Treatment2 Interventions
Patients receive 17-N-allylamino 17-demethoxygeldanamycin (17-AAG) IV over 2-6 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses of treatment beyond documentation of CR.
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor
Trials
14,080
Recruited
41,180,000+
Dr. Douglas R. Lowy
National Cancer Institute (NCI)
Chief Executive Officer since 2023
MD from New York University School of Medicine
Dr. Monica Bertagnolli
National Cancer Institute (NCI)
Chief Medical Officer since 2022
MD from Harvard Medical School